News Fulcrum Therapeutics promises new drugs for rare disorders Company launched following $55 million series A funding round.
News Agenovir secures funding for CRISPR antiviral therapies Antiviral therapy specialist Agenovir has secured $10.6 million in funding from a series A funding round.
News Caribou gains $30m funding for CRISPR-Cas platform Genetic engineering specialist Caribou Biosciences has secured $30 million in a series B funding round.
News We’re No.1 in CRISPR gene-editing race, says AstraZeneca The technology known as CRISPR/Cas9 has been described as the 'holy grail' of genetic engineering, and has become the hottest research area because of its potential to cure many diseases by
Digital On AI and computational support of biochemistry, with Alan R... Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.
Sales & Marketing Sponsored The AI imperative: Establishing the standard for modern clin... The findings from the Medidata-commissioned survey confirm that AI implementation in clinical trials has moved firmly beyond theoretical discussion.
